ClinicalTrials.gg
RecruitingNCT07118254Updated Oct 26, 2026

A PHASE II PROSPECTIVE RANDOMIZED DOUBLE-MASKED CROSSOVER STUDY ASSESSING THE SAFETY & EFFICACY OF RHPRG4 (450 μG/ML RECOMBINANT HUMAN PROTEOGLYCAN 4) COMPARED TO VEHICLE FOR THE TREATMENT OF OCULAR GRAFT-VERSUS-HOST DISEASE (OGVHD)

A Phase 2 interventional study of rhPRG4 450ug/ml and Vehicle Control in Ocular Graft Versus Host Disease, sponsored by Lubris Bio Pty Ltd. Recruiting at 3 sites in Australia. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-26.

Sponsored by Lubris Bio Pty Ltd · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 2 months later.
Updated Oct 23, 2026Primary completion movedStudy completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
15
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 20 studies in Dry Eye Syndromes with a site in Australia — 3 open to participants now, 3 under way, none of them phase 3. Dry Eye Syndromes · Australia.

Planned enrollment
19th of 20
15 · median 73
Started
2025
with 3 others
Phase 2
7 of 20
2 open now
Registered
18th of 20
by date
Lead sponsor
2 of 20
Lubris Bio Pty Ltd

Among the 20 studies in Dry Eye Syndromes with a site in Australia, this one is the 19th largest by planned enrollment, is one of 4 that started in 2025, is one of 7 in phase 2, and was the 18th registered.

Dry Eye Syndromes

1,370 studies on the registry are indexed under Dry Eye Syndromes; 209 are open to participants now.

Browse Dry Eye Syndromes studies →

Open to participants now

3 of the 20 studies in Dry Eye Syndromes with a site in Australia are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 117 Dry Eye Syndromes studies recruiting now, 74 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Dry Eye Syndromes with a site in Australia, or all of them as a file.
02

Study summary

An 84-day, prospective, randomized (1:1) vehicle controlled, double-masked pre-market, crossover study. Subjects with moderate to severe oGVHD related Dry Eye Disease Each subject will receive both treatments in random sequence, each for 28 days, separated by a 14-day vehicle washout period.

03

Conditions studied

  • Ocular Graft Versus Host Disease

Keywords

  • oGVHD
  • Dry Eye
  • Graft Versus Host Disease
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Have the ability to comprehend and provide a signed and dated consent form.
  2. Are 18-80 years of age at time of consent;
  3. Have been diagnosed with oGVHD for at least 3 months prior to giving to participate in the trial;
  4. Current use of artificial tears for the treatment of oGVHD related dry eye;
  5. Have been stably using systemic medications for at least 14 days prior to Visit 1;
  6. VAS Eye Dryness (100-point scale) score ≥ 40 mm;
  7. Average VAS score for all symptoms of dry eye (dryness, foreign body sensation, burning/stinging, itching, pain, stick feeling, blurred vision and photophobia) ≥ 25 mm, none \< 5 mm;
  8. Have Oxford corneal fluorescein staining grade of ≥ 2 using the Oxford scale in the worst performing eye
  9. Stated willingness to comply with all study procedures, attend all scheduled clinic visits, and continue participation for the duration of the study;
  10. Ability to self-administer study medication and willingness to adhere to the medication regimen.

Exclusion criteria

Exclusion Criteria:

Are currently or have a history of any ocular or systemic disorder or condition other than dry eye that based on investigator judgment will interfere with the interpretation of the study results. Examples of ocular or systemic disorders or conditions include active ocular infection, conjunctivochalasis, superior limbic keratoconjunctivitis, limbal stem cell deficiency, allergic conjunctivitis, giant papillary conjunctivitis, atopic keratoconjunctivitis, anterior basement membrane dystrophies, neurotrophic keratitis, corneal dystrophy, exposure keratitis, moderate to severe blepharitis, ocular trauma, progressive or degenerative corneal conditions, uveitis, and systemic infection; 2. History of any ocular surgery (including laser or refractive surgical procedures) or therapeutic medical devices in either eye within 30 days before study enrollment. Therapeutic medical devices include trigeminal stimulation, meibomian glad warming (excepting at home masks) or expression, intense pulsed light, low level light therapy, etc. Ocular surgeries include laser or refractive surgical procedures, insertion of punctal or punctal cauterization; Ocular surgery will not be allowed during study participation; 3. Initiation of new therapeutic modalities within 14 days of Visit 1; 4. Have a known to one of the components of the study or procedural medications; 5. Have participated in another clinical study at the same time as the present study or within 30 days of the Visit 1; 6. Have a history of drug, medication or alcohol abuse or addiction; 7. Are females of (those who are not surgically sterilized or for at least 1 year) who meet any one of the following conditions:

  1. are currently pregnant or,
  2. have a positive result on the urine pregnancy test at the Screening/Baseline Visit or,
  3. intend to become pregnant during the entire course of and 30 days after the study treatment periods, or,
  4. are breast-feeding or,
  5. not willing to use highly effective measures, such as: hormonal contraceptives - oral, implanted, transdermal, or injected and/or mechanical barrier methods, during the entire course of and 30 days after the study treatment periods; 8. Per the discretion of the investigator or designee, history of a serious physical or mental disorder that prevents the subject from attending study visits, complying with study-related procedures, and/or prevents the subject's ability to make decisions on their own; 9. Any other surgical or medical condition or finding that in the opinion of the investigator would compromise the subject's safety or participation in the study.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
15 participants (estimated)

Study arms

  • Experimental
    rhPRG4 450ug/ml

    rhPRG4 450ug/ml

    Drug: rhPRG4 450ug/ml

  • Placebo comparator
    Vehicle Control

    PBS Based Vehicle Control

    Drug: Vehicle Control

Interventions

  • DrugrhPRG4 450ug/ml

    Treatment

  • DrugVehicle Control

    PBS Based Vehicle Control

06

What researchers measure

Primary outcomes

  1. To assess the efficacy of rhPRG4 using the total corneal staining with fluorescein (Oxford Scale) compared to vehicle after 28 days of treatment

    To assess the efficacy of rhPRG4 using the total corneal staining with fluorescein (Oxford Scale) compared to vehicle after 28 days of treatment

    Time frame: Baseline to day 28

  2. To assess the efficacy of rhPRG4 using the total VAS score (sum of dryness, foreign body sensation, burning/stinging, itching, pain, sticky feeling, blurred vision and photophobia, anchors: none & severe) compared to vehicle after 28 days of treatment

    To assess the efficacy of rhPRG4 using the total VAS score (sum of dryness, foreign body sensation, burning/stinging, itching, pain, sticky feeling, blurred vision and photophobia, anchors: none \& severe) compared to vehicle after 28 days of treatment

    Time frame: From baseline to day 28

Secondary outcomes

  1. To assess the efficacy of rhPRG4 using individual VAS scores for dryness, foreign body sensation, burning/stinging, itching, pain, sticky feeling, blurred vision and photophobia (anchors: none & severe) compared to vehicle after 28 days of treatment

    To assess the efficacy of rhPRG4 using individual VAS scores for dryness, foreign body sensation, burning/stinging, itching, pain, sticky feeling, blurred vision and photophobia (anchors: none \& severe) compared to vehicle after 28 days of treatment

    Time frame: From baseline to day 28

  2. To assess the efficacy of rhPRG4 using the SANDE score compared to vehicle after 28 days of treatment

    To assess the efficacy of rhPRG4 using the SANDE score compared to vehicle after 28 days of treatment

    Time frame: From baseline to day 28

  3. To assess the efficacy of rhPRG4 using the maximum inter-eye tear osmolarity: max(OU) compared to vehicle after 28 days of treatment

    To assess the efficacy of rhPRG4 using the maximum inter-eye tear osmolarity: max(OU) compared to vehicle after 28 days of treatment

    Time frame: From baseline to day 28

  4. To assess the safety of rhPRG4 by observation of the severity of treatment-emergent adverse events over the study duration

    To assess the safety of rhPRG4 by observation of the severity of treatment-emergent adverse events over the study duration

    Time frame: From baseline to day 28

  5. To assess the safety of rhPRG4 by observation of the Best Corrected Distance Visual Acuity (BCVA)

    To assess the safety of rhPRG4 by observation of the Best Corrected Distance Visual Acuity (BCVA)

    Time frame: From baseline to day 28

  6. To assess the safety of rhPRG4 by observation of signs evaluated by safety examination (ophthalmic examination plus slit lamp examination (SLE) of meibomian glands, eyelid Erythema, eyelid oedema, lashes, conjunctival erythema, lens, iris, anterior chamb

    To assess the safety of rhPRG4 by observation of signs evaluated by safety examination (ophthalmic examination plus slit lamp examination (SLE) of meibomian glands, eyelid Erythema, eyelid oedema, lashes, conjunctival erythema, lens, iris, anterior chamber, hyperemia, corneal transparency \& corneal neovascularization)

    Time frame: From baseline to day 28

  7. To assess the safety of rhPRG4 by observation of intraocular pressure (IOP)

    To assess the safety of rhPRG4 by observation of intraocular pressure (IOP)

    Time frame: From baseline to day 28

07

Study locations

2 of 3 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2025 (actual). Primary completion is estimated for Mar 2027, 18 months after the start.

Of 75 industry-sponsored phase 2 interventional studies under Dry Eye Syndromes, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 11. This study's planned 18 months is above that.

Counting every sponsor, half of 91 studies reached it within 7 months; a quarter within 5 and three quarters within 12.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 23, 2026: primary completion Sep 2026 → Mar 2027 and completion Dec 2026 → Jun 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 5, 2025
First posted
Aug 12, 2025
StartActual
Sep 17, 2025
Primary completionEst.
Mar 2027was Sep 2026
CompletionEst.
Jun 2027was Dec 2026
Last update
Oct 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Sep 2026→Mar 2027
Oct 23, 2026
Study completion
Dec 2026→Jun 2027
Oct 23, 2026
Contact
Study contact's phone or email changed: e•••@lubris.net→e•••@lubris.net. See the current contact
Oct 23, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Royal Melbourne Hospital · Melbourne, AustraliaContact S•••@mh.org.au→E•••@mh.org.auContact e•••@mh.org.au→E•••@mh.org.au
across 2 updates, Oct 23, 2026 – Oct 26, 2026
Show all 2 updates
  1. Oct 26, 2026
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Royal Melbourne Hospital · Melbourne, AustraliaContact S•••@mh.org.au→E•••@mh.org.auContact e•••@mh.org.au→E•••@mh.org.au
  2. Oct 23, 2026
    Primary completion Sep 2026→Mar 2027
    Study completion Dec 2026→Jun 2027
    Contact Study contact's phone or email changed: e•••@lubris.net→e•••@lubris.net. See the current contact
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Royal Melbourne Hospital · Melbourne, AustraliaContact e•••@irissurgey.com.au · •••8695→S•••@mh.org.au · •••2641Contact added e•••@mh.org.au · •••8695
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07118254
Lead sponsor
Lubris Bio Pty Ltd
Responsible party
Sponsor
First posted
Aug 12, 2025
Start date
Sep 17, 2025
Primary completion
Mar 2027 (estimated)
Completion
Jun 2027 (estimated)
Last update
Oct 26, 2026

Study contacts

Edward CEO
Contact
etruitt@lubris.net
6193394016

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion